跳至主要内容
临床试验/NCT00121069
NCT00121069已完成2 期

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

Connor, Kathryn M., M.D.2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2002年9月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
12
试验地点
2
主要终点
Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline

研究概览

简要总结

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

详细描述

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults 18-65 years of age
  • DSM-IV criteria for specific phobia according to the MINI
  • For women of childbearing potential, a negative serum pregnancy test at screening
  • Written informed consent

排除标准

  • Any current primary DSM-IV diagnosis other than specific phobia
  • History of DSM-IV substance abuse or dependence within the last months
  • Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
  • Suicide risk or serious suicide attempt within the last year
  • Clinically significant laboratory or EKG abnormality or unstable medical condition
  • For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
  • Subjects needing concurrent use of psychotropic medications

结局指标

主要结局

Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline

次要结局

  • Response based on CGI-I category

研究者

发起方
Connor, Kathryn M., M.D.
申办方类型
Indiv

研究点 (2)

Loading locations...

相似试验